Search Results

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.

Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New York City on Thursday, June 6, 2024.

Vanda Pharmaceuticals Inc. today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY ® (ponesimod) has been transferred to Vanda from a Johnson & Johnson Company, which now fully allows Vanda to commercialize PONVORY ® in the U.S.

Vanda Pharmaceuticals Inc. announced that the Company’s Board of Directors has determined that the unsolicited proposal from Cycle Group Holdings Ltd to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders.

Vanda Pharmaceuticals Inc. announced financial and operational results for the first quarter ended March 31, 2024.

Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC (“Future Pak”) to acquire the Company.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda’s petition for a writ of certiorari in its HETLIOZ ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA , Inc.